The abstract is read at the publisher; the summary is JClub's.
In mice with triple-negative breast cancer, personalized cancer cell membrane-derived nanovaccines (CCM/TA-DLNPs) enhance antitumor immunity, reprogram “cold tumor” microenvironments, and improve tumor eradication, recurrence risk, and survival.
- Why it matters: Therapeutic tumor vaccines often underperform because dendritic cells present tumor-specific antigens inefficiently, limiting downstream T-cell recognition and durable protection.
- What they did: The study built DOPCO-based ionizable glycolipid LNPs hybridized with tumor cell membranes and loaded with a TLR7/8 agonist RNA adjuvant, then assessed DC targeting, lymph node accumulation, and T-cell responses in a TNBC mouse model.
- The result: CCM/TA-DLNPs displaying multi-antigens matching the source tumor can deliver personalized antigens to DC, amplify systemic immune activation with TA, and generate long-term immunological memory that supports eradication and prevention.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.